BlackRock's Long Position in H-Shares of Jiangsu Hengrui Increases to 6.99% on Sept 30 from 5.96% - HKEX

UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 4.59% on Sept 25 from 5.17% - HKEX

Major Drugmakers Turn to China for Licensing Deals

Major Drugmakers Turn to China for Licensing Deals

Daiwa: Hengrui Pharma (01276) Reaches Licensing Deal with Novo Nordisk for HRS-1596; Total Transaction Value and Upfront Payment Both Attractive

Morgan Stanley Maintains Overweight Rating on Hengrui Pharma (01276) with HK$82 Target Price

Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Hengrui Pharma Licenses Oral GLP-1/GIP Weight-Loss Drug to Novo Nordisk in Deal Worth Up to $2.6 Billion

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral Glp-1/Gip Dual Receptor Agonist Hrs-1596

China's Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug

Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project

Hengrui Pharma Licenses GLP-1/GIP Drug HRS-1596 to Novo Nordisk in Deal Worth up to USD 2.6 Billion

Jiangsu Hengrui Pharmaceuticals - Entering into License Agreement for Hrs-1596 with Novo Nordisk a/S

Jiangsu Hengrui Pharmaceuticals - Potential Total Value of Agreement up to $2.6 Bln Contingent on Achievement of Applicable Development, Others

Jiangsu Hengrui Pharmaceuticals - Dedal Includes $300 Mln Upfront Payment

Jiangsu Hengrui Pharmaceuticals - Co Also Eligible to Receive Royalties Based on Net Sales of Hrs-1596 Within Licensed Territory

Blackrock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.32%, Says HKEX

UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.23% on Sept 21 from 4.43% - HKEX

HENGRUI PHARMA Spends RMB 11.37 Million Buying Back 250,000 A-Shares on September 23